The University of Texas MD Anderson Cancer Center received a $647,998 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award will fund research to develop image-guided, bidirectional EphB4 agonist-based therapy for ovarian cancer over a 4-year period from September 1, 2023 to August 31, 2027. MD Anderson, a comprehensive cancer treatment and research center, has extensive experience conducting basic, translational, clinical, and public health cancer research through federal grant funding. The University of Texas System also serves as a subrecipient on various federal grants supporting research across diverse areas. This award will contribute to the program's objective of transforming health care for service members and the public through innovative and impactful biomedical research, particularly focused on developing novel cancer treatment approaches.
Generated 3/26/24, 8:32 AM